Skip to main content

Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates.

Publication ,  Journal Article
Mollan, KR; Eron, JJ; Krajewski, TJ; Painter, W; Duke, ER; Morse, CG; Goecker, EA; Premkumar, L; Wolfe, CR; Szewczyk, LJ; Alabanza, PL ...
Published in: medRxiv
June 25, 2021

BACKGROUND: While SARS-CoV-2 infectious virus isolation in outpatients with COVID-19 has been associated with viral RNA levels and symptom duration, little is known about the host, disease and viral determinants of infectious virus detection. METHODS: COVID-19 adult outpatients were enrolled within 7 days of symptom onset. Clinical symptoms were recorded via patient diary. Nasopharyngeal swabs were collected to quantitate SARS-CoV-2 RNA by reverse transcriptase polymerase chain reaction and for infectious virus isolation in Vero E6-cells. SARS-CoV-2 antibodies were measured in serum using a validated ELISA assay. RESULTS: Among 204 participants with mild-to-moderate symptomatic COVID19, the median nasopharyngeal viral RNA was 6.5 (IQR 4.7-7.6 log10 copies/mL), and 26% had detectable SARS-CoV-2 antibodies (IgA, IgM, IgG, and/or total Ig) at baseline. Infectious virus was recovered in 7% of participants with SARS-CoV-2 antibodies compared to 58% of participants without antibodies (probability ratio (PR)=0.12, 95% CI: 0.04, 0.36; p=0.00016). Infectious virus isolation was also associated with higher levels of viral RNA (mean RNA difference +2.6 log10, 95% CI: 2.2, 3.0; p<0.0001) and fewer days since symptom onset (PR=0.79, 95% CI: 0.71, 0.88 per day; p<0.0001). CONCLUSIONS: The presence of SARS-CoV-2 antibodies is strongly associated with clearance of infectious virus isolation. Seropositivity and viral RNA levels are likely more reliable markers of infectious virus clearance than subjective measure of COVID-19 symptom duration. Virus-targeted treatment and prevention strategies should be administered as early as possible and ideally before seroconversion. CLINICALTRIALSGOV IDENTIFIER: NCT04405570.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

medRxiv

DOI

Publication Date

June 25, 2021

Location

United States
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mollan, K. R., Eron, J. J., Krajewski, T. J., Painter, W., Duke, E. R., Morse, C. G., … Fischer, W. A. (2021). Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates. MedRxiv. https://doi.org/10.1101/2021.05.28.21258011
Mollan, Katie R., Joseph J. Eron, Taylor J. Krajewski, Wendy Painter, Elizabeth R. Duke, Caryn G. Morse, Erin A. Goecker, et al. “Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates.MedRxiv, June 25, 2021. https://doi.org/10.1101/2021.05.28.21258011.
Mollan KR, Eron JJ, Krajewski TJ, Painter W, Duke ER, Morse CG, et al. Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates. medRxiv. 2021 Jun 25;
Mollan, Katie R., et al. “Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates.MedRxiv, June 2021. Pubmed, doi:10.1101/2021.05.28.21258011.
Mollan KR, Eron JJ, Krajewski TJ, Painter W, Duke ER, Morse CG, Goecker EA, Premkumar L, Wolfe CR, Szewczyk LJ, Alabanza PL, Loftis AJ, Degli-Angeli EJ, Brown AJ, Dragavon JA, Won JJ, Keys J, Hudgens MG, Fang L, Wohl DA, Cohen MS, Baric RS, Coombs RW, Sheahan TP, Fischer WA. Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates. medRxiv. 2021 Jun 25;

Published In

medRxiv

DOI

Publication Date

June 25, 2021

Location

United States